Your search for ‘Reed Smith’ returned 9,636 results

Reed Smith's Robert Jaworski recently wrote an article on New York Attorney General Eric Schneiderman's settlement agreement (Agreement) with the three national consumer reporting agencies (CRAs).

On August 28, 2015, the Health Services Resources Administration (HRSA) published long-awaited 340B Drug Pricing Program Omnibus Guidance.

As Reed Smith attorney Jim Beck points out, there are plenty of differences in approach, from states that employ the heeding presumption, to those that recognize it in a limited capacity, and those that reject it entirely.

The Centers for Medicare & Medicaid Services' Medicare Shared Savings Program final rule offers potential opportunities as well as risks to health care providers and suppliers interested in forming accountable care organizations (ACOs).

CMS has scheduled a June 27, 2019 listening session to get public feedback on its recent draft guidance on how state surveyors should evaluate hospital co-location arrangements for compliance with the Medicare hospital conditions of participation

The Centers for Medicare & Medicaid Services (CMS) has proposed regulations "to reduce burden and to facilitate compliance" under the physician self-referral law known as the Stark Law.

The Drug & Device Law blog recently posted an analysis of an interesting case, United States ex rel. Solis v. Millennium Pharmaceuticals, Inc.,

The Health Resources and Services Administration is once again delaying the effective date of its January 5, 2017 rule on 340B drug pricing program ceiling price calculation and civil monetary penalties.

The number of qui tam actions brought under the False Claims Act has increased dramatically over the past several years, as the incentives for bringing such claims have grown

When the New Jersey Supreme Court ruled in Perez v. Wyeth Lab, Inc. that if pharmaceutical manufacturer directly markets to consumers, the learned intermediary doctrine does not apply, it was deemed a "revolutionary," decision.

The FDA also recently announced that its "fair balance" doctrine may be amended to only require companies to recite or print a product's most prominent and common side effects during television commercials.

The HITECH Act—including the HITECH Final Rule's provisions about HIPAA, data privacy, security, and breach notification—is an issue we have covered in detail previously.

The bloggers at Drug & Device Law regularly keep up-to-date scorecards and cheat sheets on a host of topics useful to drug and device manufacturers in product liability litigation.

The House Oversight and Government Reform Committee recently passed the revised "Modernizing Government Technology Act," and the bill will proceed to the House floor for a vote.

According to a recent study, the median amount of time between a breach of a company’s cybernetwork and the discovery of that breach is 229 days.

In April, 2013 the 2nd Circuit concluded that certain works of the well-known appropriation artist, Richard Prince, which used Patrick Cariou’s photographs in a series of collages, constituted fair use.

While attorney-client privilege is a well-established concept, application of the policy becomes murky when the communications in question are between a client and an outside PR firm.